- Home
- SLRX vs CANF Comparison
SLRX vs CANF Comparison
Compare SLRX & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLRX
- CANF
- Stock Information
- Founded
- SLRX N/A
- CANF 1994
- Country
- SLRX United States
- CANF Israel
- Employees
- SLRX N/A
- CANF N/A
- Industry
- SLRX Biotechnology: Pharmaceutical Preparations
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- SLRX Health Care
- CANF Health Care
- Exchange
- SLRX Nasdaq
- CANF Nasdaq
- Market Cap
- SLRX N/A
- CANF 7.9M
- IPO Year
- SLRX N/A
- CANF N/A
- Fundamental
- Price
- SLRX $0.78
- CANF $1.12
- Analyst Decision
- SLRX
- CANF Strong Buy
- Analyst Count
- SLRX 0
- CANF 2
- Target Price
- SLRX N/A
- CANF $14.00
- AVG Volume (30 Days)
- SLRX 45.8K
- CANF 444.9K
- Earning Date
- SLRX 05-16-2025
- CANF 05-20-2025
- Dividend Yield
- SLRX N/A
- CANF N/A
- EPS Growth
- SLRX N/A
- CANF N/A
- EPS
- SLRX N/A
- CANF N/A
- Revenue
- SLRX N/A
- CANF $674,000.00
- Revenue This Year
- SLRX N/A
- CANF $461.72
- Revenue Next Year
- SLRX N/A
- CANF N/A
- P/E Ratio
- SLRX N/A
- CANF N/A
- Revenue Growth
- SLRX N/A
- CANF N/A
- 52 Week Low
- SLRX $0.45
- CANF $1.02
- 52 Week High
- SLRX $7.20
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- SLRX 52.55
- CANF 40.36
- Support Level
- SLRX $0.68
- CANF $1.02
- Resistance Level
- SLRX $0.74
- CANF $1.20
- Average True Range (ATR)
- SLRX 0.05
- CANF 0.06
- MACD
- SLRX 0.02
- CANF 0.01
- Stochastic Oscillator
- SLRX 87.21
- CANF 43.18
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).